Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19808558 | 0.77 | EPHX2 (0.40) | EPHX2HSD11B1 | |
| SCHEMBL15224188 | 0.75 | L3MBTL1 (0.66) | L3MBTL1EPHX2HSD11B1ALDH1A1HSD17B10 | |
| SCHEMBL19808153 | 0.74 | L3MBTL1 (0.63) | L3MBTL1EPHX2HSD11B1ALDH1A1HSD17B10 | |
| SCHEMBL12344537 | 0.73 | L3MBTL1 (1.00) | L3MBTL1EPHX2HSD11B1ALDH1A1HSD17B10 | |
| SCHEMBL9743896 | 0.73 | L3MBTL1 (0.73) | L3MBTL1EPHX2HSD11B1ALDH1A1HSD17B10 | |
| SCHEMBL25358145 | 0.73 | L3MBTL1 (0.68) | L3MBTL1EPHX2HSD11B1ALDH1A1HSD17B10 | |
| SCHEMBL9744305 | 0.73 | L3MBTL1 (0.68) | L3MBTL1EPHX2HSD11B1ALDH1A1HSD17B10 | |
| SCHEMBL4229104 | 0.72 | L3MBTL1 (0.61) | L3MBTL1EPHX2HSD11B1ALDH1A1HSD17B10 | |
| SCHEMBL1923226 | 0.72 | L3MBTL1 (0.61) | L3MBTL1EPHX2HSD11B1ALDH1A1HSD17B10 | |
| SCHEMBL1193302 | 0.71 | L3MBTL1 (0.60) | L3MBTL1EPHX2HSD11B1ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2019-02-12 | — | — | US | disclosed |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | IDO1, IDO2, TDO2 | L3MBTL1 4746/4885EPHX2 1124/4885CA1 1754/4885 |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | IDO1, IDO2, TDO2 | L3MBTL1 4746/4885EPHX2 1124/4885CA1 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.